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Abstract
Background: To explore the cortical network sustaining action myoclonus and to found markers of the resulting
functional impairment, we evaluated the distribution of the cortico-muscular coherence (CMC) and the frequency
of coherent cortical oscillations with magnetoencephalography (MEG). All patients had EPM1 (Unverricht-Lundborg)
disease known to present with prominent and disabling movement-activated myoclonus.
Methods: Using autoregressive models, we evaluated CMC on MEG sensors grouped in regions of interests (ROIs)
above the main cortical areas. The movement was a repeated sustained isometric extension of the right hand and
right foot. We compared the data obtained in 10 EPM1 patients with those obtained in 10 age-matched controls.
Results: As expected, CMC in beta band was significantly higher in EPM1 patients compared to controls in the ROIs
exploring the sensorimotor cortex, but, it was also significantly higher in adjacent ROIs ipsilateral and contralateral
to the activated limb. Moreover, the beta-CMC peak occurred at frequencies significantly slower and more stable
frequencies in EPM1 patients with respect to controls. The frequency of the beta-CMC peak inversely correlated
with the severity of myoclonus.
Conclusions: the high and spatially extended beta-CMC peaking in a restricted range of low-beta frequencies in
EPM1 patients, suggest that action myoclonus may result not only from an enhanced local synchronization but also
from a specific oscillatory activity involving an expanded neuronal pool. The significant relationship between beta-
CMC peak frequency and the severity of the motor impairment can represent a useful neurophysiological marker
for the patients’ evaluation and follow-up.
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Background
Neocortex is largely involved in the pathophysiology of
movement disorders either directly, as a probable gener-
ator of particular types of myoclonus or rhythmic
tremors or indirectly, by modulating the effect of sub-
cortical generators. In pathological conditions, various
studies investigated cortico-muscular coherence (CMC)
between electroencephalography (EEG) or MEG and
surface electromyography (EMG) signals with the aim of
evaluating the relationship between cortical oscillations
and EMG bursts. The consistent results of CMC analysis
performed by Fast Fourier Transform or autoregressive
(AR) methods in progressive myoclonic disorders [1–3]
indicated that this approach is particularly effective in
investigating the cortical origin of the jerks. Namely, this
applies to the case of rhythmic myoclonus [2] or other
subtle movement disorders such “cortical tremors” ([4, 5]
for a review). Therefore, coherence analysis gained prac-
tical diagnostic value in rare or newly identified myoclonic
syndromes, as well as in the examination of individual
patients [6–8] Moreover, some observations also sug-
gested a quantitative relationship between CMC values
and the severity of the impairment resulting from this
movement disorder [9].
Data obtained from patients with movement-activated
jerks indicate that CMC between the sensorimotor
region and the activated limb is mostly evident in beta-
band, the same band in which CMC occurs during
motor task in healthy subjects [10–12]. These observa-
tions suggest that “pathological” CMC in patients with
jerky movement disorders may result from a purely
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quantitative distortion of the physiological CMC. How-
ever, the physiopathological mechanisms regulating the
network responsible for enhanced CMC is still not
clearly identified.
In this study we investigated the spreading of CMC
using MEG signals recorded from patients with EPM1
(MIM #254800), a genetically determined neurological
disorder characterized by prominent movement-activated
myoclonus [13, 14], therefore representing a disease
“model” for this type of movement disorder. We
performed this study with the aim of evaluating the extent
and the topographical distribution of the brain cortico-
muscular network involved in the generation of myoclo-
nus and the frequency characteristics of the peak at which
CMC occurs. Several studies have already established the
presence of high coherence values between EEG or MEG
activity and myoclonic EMG bursts [3, 15], but only a few
of them compared the extent of the cortico-muscular
network activated in healthy and pathological conditions
during the same motor task [16]. MEG signals are suitable
to perform this investigation due to the lower interference
of superficial tissues and because MEG signals, in contrast
to EEG, do not need any reference potentially susceptible
to distort CMC amplitude and phase relationships. The
final goal was the achievement of objective measures suit-
able to improve our understanding of the dysfunctional
mechanism underlying myoclonus, to quantify the severity
of motor impairment and, possibly, to find biomarkers
able to monitor changes due to pharmacological and non-
pharmacological treatments.
Methods
We included ten patients with a diagnosis of EPM1
(three women) confirmed by the genetic finding of the
homozygous expansion mutation of the CSTB gene or
the compound heterozygous (expansion and point)
mutation. The mean disease duration in EPM1 patients
was 29.2 ± 4.7 years. The predominant symptom in all of
the patients was myoclonus, whereas mental decline was
minimal or absent; no subjects had neurological comor-
bidities. Myoclonus severity was scored according to a
simplified functional scale with five degrees [17]
(Table 1). All patients received an anti-myoclonic and
antiepileptic treatment always including valproate. Only
three of them received low doses of benzodiazepines
(Table 1). This pharmacological therapy was able to con-
trol seizures in all of the patients. We compared the re-
sults of the MEG–EMG analyses of the EPM1 patients
with those obtained in 10 healthy (six women) volun-
teers who underwent the same type of neurophysio-
logical examination. The mean age at the time of the
MEG recordings was similar in EPM1 and controls
(43.3 ± 15.4 years and 40.3 ± 15.9 years).
We recorded MEG signals in a magnetically shielded
room (VACUUMSCHMELZE GmbH & Co KG, Hanau
Germany) with a 306-channel whole head MEG system
(Neuromag Triux, Elekta Oy, Sweden). Signals were
filtered in the band 0.1-330 Hz and sampled at 1 kHz.
Bipolar electro-oculographic and electrocardiographic
signals were acquired in order to monitor and remove
ocular and cardiac artefacts. Subjects laid in supine
position with eyes closed.
The subject’s head position inside the MEG helmet was
continuously monitored by five head position identifica-
tion (HPI) coils located on the scalp. The locations of
these coils, together with three anatomical landmarks
(nasion, right and left preauriculars), and additional scalp
points were digitized before the recording by means of a
3D digitizer (FASTRAK, Polhemus, Colchester, VT).
Surface EMG signals were simultaneously recorded
from pairs of electrodes placed bilaterally 2–3 cm
apart over the belly of the right and left flexor and
extensor wrist muscles and of right tibialis anterior
and gastrocnemius.
Table 1 Main parameters of the disease and disability resulting from myoclonus; pharmacological treatment
Patient N, gender Age (years) Disease Onset (years) Disease Duration (years) Score Treatment (daily dose in mg)
#1, F 28 11 17 2 VPA 1200, LEV 1000, TPM 200
#2, M 27 16 11 1 VPA 1750, LEV 3000
#3, M 43 14 29 1 VPA 1500, ZNS 200
#4, M 52 17 35 1 VPA 2400, PB 50
#5, F 23 11 12 2 VPA 1150, LEV 1750
#6, M 54 15 39 2 VPA 2500, ZNS 200
#7, M 50 16 34 4 VPA 1800, CZP 1, TPM 300, ZNS 500
#8, M 60 16 44 3 VPA 1200, PB 150, CZP 1
#9, F 70 14 56 5 VPA 1300, LEV 2000, TPM 100, CZP 4
#10, F 26 11 15 3 VPA 1750, ZNS 300
Legend: Score: assessed according to a simplified functional scale [17]: treatment: VPA valproate, TPM topiramate, LEV levetiracetam, ZNS zonisamide, PB
phenobarbital, CZP clonazepam
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MEG and polygraphic signals were recorded at rest,
and during periods of maintained right wrist or foot
extension (five sequences of 1 min each).
Data processing
MEG signals were pre-processed off-line with the tem-
porally extended signal space separation method (tSSS,
[18]) implemented in the Maxfilter 2.2 (Elekta Neuro-
mag Oy, Helsinki, Finland) to suppress external interfer-
ences and correct for head movements, and next filtered
in the 1.6-100 Hz band with a zero phase digital filter.
The MEG system used for this study is endowed with
204 planar gradiometers (102 with derivative along
longitude (y-axis) and 102 along latitude (x-axis), and
102 magnetometers. In this study, we used the planar
gradiometers, which are mainly sensitive to sources
close to the sensor array, and relatively insensitive to
homogenous fields; moreover, the topographic maps
obtained from gradiometers show maxima just over
the sources, whereas they show patterns with one posi-
tive and one negative maxima symmetrically arranged
perpendicularly to the source axis when obtained from
magnetometers. As far the type and combinations of
gradiometers, different approaches were used in previ-
ous connectivity studies. Some authors considered the
whole set [19], whereas others chose either to select
the orientation showing the highest connectivity values
[20], or a combined value of each gradiometer couples
[21, 22]. We chose to report results obtained from the
set of 102 gradiometers with derivative along the y-
axis (y-gradiometers), since they showed in all of the
subjects a clearer and more stable CMC response
during the voluntary movements, in particular over the
sensorimotor cortex, with respect to gradiometers with
derivative along the x-axis.
CMC was estimated by means of a blockwise bivari-
ate AR model. The AR model order was determined
using the multichannel version of the Akaike criterion
as a guideline and the goodness of the identification
was verified by means of ‘portmanteau’ chi-square and
Anderson’s tests [23, 24]. Coherence was defined as:







Sxx fð ÞSyyðf Þ
where Sxx (f ) and Syy (f ) are the power spectral densities
of the MEG and EMG channels, and Sxy (f ) is the cross-
spectral density. The critical value for the null hypoth-
esis of zero-coherence at a significance level of 0.01 was
computed according to [25], taking into account that the
degree of freedom of an AR model is given by N/p [26],
where N is the number of samples, p the model order,
and that the asymptotic variance of the AR spectral
estimate is similar to that of the smoothed periodogram
with the same number of degrees of freedom [27, 28].
About three minute of the MEG and EMG signals free
from artefacts was selected for the analysis, normalised
by subtracting the mean value and dividing the result by
the standard deviation, and then divided into non-
overlapping 1-s epochs. The epochs were considered
multiple realisations of the same process and the autore-
gressive coefficients were estimated by means of the
Levinson-Robinson-Wiggins algorithm [29].
In order to evaluate CMC patterns in different areas,
the sensors were grouped into 12 regions of interest
(ROIs): right (RF), and left (LF) frontal, right (RLP) and
left (LLP) lateral parietal, right (RO) and left (LO) occipi-
tal, frontal vertex (FV), occipital vertex (OV), left and right
parietal vertex (VLP, VRP), left and right temporal (LT,
RT), according to the layout of sensor elements, and the
CMC within each ROI was averaged.
All of the analyses were made using custom-written
routines in Matlab (Version 8.3, R2015b; Mathworks
Inc., Natick, MA, USA), which also contained modified
functions from the Biosig toolbox [30].
Statistical analysis
Fisher’s Z transformation was applied to CMC values in
order to normalize their distribution. The data were statis-
tically analyzed using the SPSS software (version 17, SPSS
Inc. Chicago, IL, USA). We used repeated measures ana-
lysis of variance (RM-ANOVA) at a significance level of
5 % to assess the effects of the between group (EPM1
patients and controls) and the within-group (mean beta-
CMC coherence in ROIs) factors. The sphericity assump-
tion was evaluated using Mauchley’s test, and the
Greenhouse-Geisser correction was applied when appro-
priate. When RM-ANOVA showed significant main
effects or interactions, post hoc analysis (ANOVA) was
used. We applied non-parametric U-Mann or Wilcoxon
tests to compare the ordinal values (e.g. number of gradi-
ometers), and the Pearson’s correlation analysis to evaluate
the relationship between the CMC peak magnitude or
frequencies and clinical parameters.
Results
During the execution of both upper and lower limb
motor tasks, all subjects showed significant beta-CMC
on more than one sensor exploring parietal and/or
frontal areas.
CMC magnitude and distribution
Comparing EPM1 with controls, RM-ANOVA showed sig-
nificant “between subjects” differences for the mean beta-
CMC magnitude during both upper (F (1,18) = 12.24,
p = 0.003) and lower limb (F (1,18) = 4.8, p = 0.034)
motor task.
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For the right upper limb motor task, post-hoc tests
performed comparing different ROIs, showed significant
differences between EPM1 patients and controls on those
ROIs including the brain areas physiologically activated
during the motor task (e.g. lateral parietal ROIs) (Fig. 1a),
but also the bilateral parietal paramedian (vertex) and the
left temporal ROI. During the right lower limb motor task,
significantly higher beta-CMC was observed in EPM1
patients in sensors located on left lateral parietal, bilateral
vertex ROIs and left temporal ROI (Fig. 1b).
Overall, the number of y-gradiometers showing supra-
threshold beta-CMC was significantly higher in EPM1
patients than in the controls for the upper limb (median
51.0, Q1 26.75 vs. median 10.0, Q1 4.75; p < 0.001; Fig. 2a
and c) and for the lower limb (median 42.0, Q1 31.00 vs.
median 11.0, Q1 6.0; p = 0.001; Fig. 2b and d).
Post-hoc tests indicated that the number of gradiome-
ters showing supra-threshold beta-CMC was higher in
EPM1 patients also in the ROIs not showing significantly
higher mean beta-CMC values, including bilateral frontal
ROIs, and left occipital ROIs both in case of upper limb
and lower limb motor task (Fig. 2e and f).
Frequency of CMC peaks
The mean frequency of beta-CMC peaks was signifi-
cantly lower in EPM1 patients than in controls during
both upper (16.19 ± 0.71 vs. 22.28 ± 1.24; F (1,18) = 17.23
p < 0.001) and lower limb (16.34 ± 0.62 Hz vs. 21.11 ±
0.9.0 Hz; F (1,18) = 20.34, p < 0.001) motor task. As
shown in Fig. 3a and b, EPM1 patients showed quite
uniform CMC peak frequencies during both upper and
lower limb tasks, while controls showed a more scat-
tered frequency distribution. Moreover, intra-subject
variability was lower in EPM1 patients than in controls,
as testified by the smaller standard error (shaded areas
in Fig. 3a and b). Therefore the peak frequency was
rather consistent in individual EPM1 patients but vari-
able in individual controls, as exemplified in the panels
c-f of Fig. 3, showing the mean coherence spectra
obtained from all y-gradiometers during the upper limb
motor task in two representative EPM1 patients (c and d)
and in two controls (e and f).
Both EPM1 patients and controls also showed a CMC
peak in the theta-alpha band (from 6 to 13 Hz), whose
mean frequency was slower in EPM1 patients (see exam-
ples in Fig. 3e and f (upper limb 6.7 ± 0.23 Hz vs. 9.26 ±
0.33 Hz, p < 0.001; lower limb 6.70 ± 0.23 Hz vs. 9.36 ±
0.33 Hz; p < 0.001). Considering the ROIs primarily in-
volved in CMC (LF, LLP, VLP, LT) we found that, both
in case of upper and lower limb motor tasks, the mean
Fig. 1 Beta-CMC magnitude during the motor task. Each box
represents the mean values and the SEM measured in EPM1 patients
(in red) and controls (in blue) during upper (a) and lower limb (b)
motor tasks; whiskers represent the 10–90 % of the maximal values; * =
p < 0.05; ** = p < 0.01; UL: upper limb, LL: lower limb, LF: left frontal, VF:
vertex frontal, RF: right frontal, LP: left parietal, VLP: vertex left parietal,
VRP: vertex right parietal, RP: right parietal, LO: left occipital, VO: vertex
occipital, RO: right occipital, LT: left temporal, RT: right temporal)
Fig. 2 Y-gradiometers with supra-threshold beta-CMC during the
motor task. Topographical representation of MEG sensors number
showing significant beta-CMC in EPM1 patients and controls during
upper limb (a and c, UL) and lower limb (b and d, LL) motor tasks. Plots
e and f display the number of sensors in ROIs between EPM1 patients
(in red) and controls (in blue) (each box represents the 25° and 75°
percentile). (* = p < 0.05; ** = p < 0.01). Abbreviations as in Fig. 1
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theta-alpha-CMC value was significantly lower than
those of beta-CMC in EPM1 patients, while this not oc-
curred in controls, (upper limb: 0.004 ± 0.001 vs. 0.026 ±
0.006 in EPM1 patients, p = 0.008 and 0.003 ± 0.001 vs.
0.005 ± 0.001 in controls) (lower limb: 0.004 ± 0.001 vs.
0.013 ± 0.004, P = 0.009 in EPM1 patients and, 0.003 ±
0.001 vs. 0.003 ± 0.001 in controls).
Relationship between MEG-EMG coherence and clinical
parameters
In controls, we did not find any significant relationship
between age at the time of MEG recording and beta-
CMC magnitude, number of y-gradiometers showing
supra-threshold beta-CMC or frequency of beta-CMC
peaks. In EPM1 patients, the magnitude of beta-CMC
evaluated on the left parietal ROI during the right upper
limb task slightly decreased with age (which paralleled
the duration of the disease) (rho = −0.790, p = 0.007).
In EPM1 patients, the severity of myoclonus (Table 1)
was not explicitly related to age or disease duration (rho =
0.503, p = 0.139). By evaluating the relationship between
myoclonus severity and beta-CMC peaks, we found that
only the beta-CMC peak frequency, but not its magnitude,
significantly correlated with the myoclonus functional
score. During the upper limb motor task, this was true ei-
ther considering the overall mean frequency values (rho =
0.843; p = 0.002) (Fig. 4), or frontal, parietal and left tem-
poral ROIs, independently. During the lower limb motor
task we found a similar relationship between the overall
mean values of beta-CMC frequency and severity of myo-
clonus (rho = 0.698; p = 0.025) but not for individual ROIs.
Discussion
Our results, indicating significantly higher beta-CMC
values in EPM patients compared to controls agree
with previous findings obtained in patients with pro-
gressive myoclonus epilepsies both on EEG and MEG
data [1–3, 15], but they also reveal the presence of
significant beta-CMC involving other regions besides
parietal and frontal areas contralateral to the activated
limb, and point out a significant shift of the beta CMC
peak towards low beta frequencies in EPM1 patients.
Our evidences agree with those obtained by [15] who
found that the amplitude of the dominant coherent
peaks were 2–4 fold compared with the healthy controls
and reported an additional ipsilateral coherent activity in
the majority of patients. Furthermore, our findings indi-
cate that the cortical area involved in the coherent
network is more extended with respect to sensorimotor
Fig. 3 Frequency of beta-CMC peaks during the motor task. Beta-CMC
peak frequency in EPM1 patients and controls during the upper (a, UL)
and lower (b, LL) limb motor tasks in the different macro areas. The
shaded areas represent the standard error. Panels (c-f) display
representative examples of CMC spectra on all sensors measured
in two EPM1 patients (#1 and #3, c and d) and in two controls
(e and f). Abbreviation as in Fig. 1
Fig. 4 Relationship between beta CMC peaks and severity of
myoclonus. Plot of the coherent beta-CMC peak mean frequency during
upper limb (UL) (a) and lower limb (LL) (b) motor task vs. functional
score, describing the severity of myoclonus in EPM1 patients. Lines
represent the linear fitting of the mean values measured in each patient
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cortex contralateral to activated limb and consistently
includes ipsilateral sensorimotor cortex and sensors
located in adjacent cortices. We consider that an import-
ant and new finding is the coupling between peculiar
low-beta frequencies of the dominant coherent peak
with abnormally high CMC, a peculiar characteristic
of myoclonus-related oscillations and correlate with
motor disability.
The observation of a significant CMC distribution on
wider cortical areas is also in line with our previous
study performed on EEG using the generalized partial
directed coherence [16], where we found that patients
with EPM1 consistently have a robust outflow towards the
activated muscles compared to controls, involving, besides
the contralateral hemisphere, the one ipsilateral to the acti-
vated limb. Likewise, we previously found in EPM1 pa-
tients a widening of the cortical areas participating in the
generation of pre-movement alpha-desynchronization [31].
In the present study, the use of high density MEG sen-
sors and the absence of any signal reference issue, differ-
ently from EEG signals, certainly contributed in revealing
the great extent of the synchronization pattern involving
contralateral premotor and temporal areas, together with
sensorimotor areas ipsilateral to the activated limb.
The involvement of pre-motor and ipsilateral motor cor-
tices into the pathophysiology of segmental action myoclo-
nus found in EPM1 patients while performing a motor
task may derive from a “compensatory” phenomenon, as
previously assumed for patients with other type of motor
dysfunctions [32]. However, it can also reveal that the
mechanism sustaining action myoclonus originates from
intrinsic behaviour and extent of the oscillating neuronal
pool. Indeed, an important finding concerns the frequency
of the myoclonus-related CMC peak in beta-band, which
was consistently and significantly slower in EPM1 patients
compared to that estimated during muscle contraction in
healthy subjects; moreover, in patients the CMC peaks
occurred in a narrow frequency range, whereas in controls
it occurred at more scattered frequencies.
These findings suggest that myoclonus does not result
from merely enhanced CMC in beta-band, but from os-
cillations occurring in a restricted frequency range at-
tributable to a specific rearrangement of the involved
neuronal pool. We found similar slowing in the beta
event-related synchronization/desynchronization (ERD-
ERS) during simple motor tasks [31, 33].
Silén et al. 2000 [34] reported a slower CMC peak fre-
quency in beta band in patients with EPM1 studied with
MEG and ascribed this slowing to degenerative changes
in the brain or to drug treatment. In healthy subjects,
MEG studies showed that the frequency of beta oscilla-
tions tends to decrease (whereas power increase) with
the administration of benzodiazepine [35] or with aging
[36]. In our study, we did not observe an age-related
change in beta-CMC magnitude or peak frequency in
healthy controls. Actually, our groups included younger
subjects, on average, than those studied by [36]; thus, it
is possible that we did not capture these variations. As
well, even if our patients took antiepileptic drugs, only
three of them took benzodiazepines. Thus, we have no
reasons to consider that the pharmacological treatment
played a relevant role in slowing the beta-CMC peak
frequency. The coherent beta-CMC peak, in fact, was
not only significantly slower in patients than in controls
but also showed a limited variability among different
patients. Moreover, we found a significant association
between the beta-CMC peak frequency and the severity
of myoclonus.
The lower beta-CMC peak frequency found in EPM1
patients, and its consistency along many sensors and
epochs, indicates that this measure can be a useful bio-
marker to evaluate the degree of the dysfunctional cortical
network in PME. Indeed, the beta-CMC peak frequency
found in our EPM1 patients was lower (or in a lowest beta
range) compared to the values observed not only in our
control group, but with values found in healthy subjects
reported in other studies. In fact, healthy peak frequencies
measured during isometric muscle contraction commonly
range from 15 to 30 Hz [2, 10, 11, 37, 38], and only a few
studies detected slower frequencies (6–15 Hz) in some
individuals [37].
In addition to beta-CMC, we also found coherent
peaks in theta-alpha band, in agreement with findings
obtained from healthy subjects [12, 39]. In our controls,
theta-alpha-CMC was significantly higher than in EPM1
patients. We can just hypothesize that in controls this
theta-alpha-CMC represents a residual mu component
persisting in spite of the motor activity.
Most data obtained in patients and in the animal model
of EPM1 [40] support a loss of GABA inhibition. In fact,
both transcranial magnetic stimulation protocols [41, 42]
on patients, and experiments performed on the EPM1
mouse model indicated reduced intracortical GABA-me-
diated inhibition and loss of GABA-interneurons [43,
44]. However, other data, obtained in a large group of
EPM1 patients, conversely support an increased GABA
inhibition, possibly deriving from a compensatory
mechanism to counteract hyperexcitability [45].
Interneurons are anyway implied not only in local
feedback inhibition but, directly, in the generation and
modulation of cortical oscillations [46], and the effect of
GABA agonists on oscillatory networks appears to be
not simply predictable. For instance, the effect of GABA
agonists seems to be both dose dependent [47] and
affected by receptor desensitization, thus making diffi-
cult to infer the final effect of GABA in complex oscilla-
tory networks. Moreover, recent data proposed that beta
activity reactive to movement could have a different
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origin, partially independent from GABA inhibition [48].
Therefore, our hypothesis of a peculiar oscillatory state
occurring in neocortical areas as responsible for the
generation of action myoclonus is not conflicting with
previously described or hypothesized GABA-dependent
mechanisms. Moreover, the present observation could
be in line with the hypothesis declaring that hypersyn-
chronous oscillations in beta-band limit the ability of
neurons to code information in time and space, and thus
sustains myoclonic bursts [49].
The observation of a significant relationship between
the frequency of the beta-CMC peak and the severity of
myoclonus on both upper and lower limb (impairing
motor ability and autonomous walk), independently
from the disease duration, may also suggest that the
coupling between significantly high CMC, low-beta peak
frequency and functional movement impairment can
represent a useful marker for the neurophysiological
evaluation and follow-up of EPM1 patients during
pharmacological or rehabilitative treatments. This rela-
tionship was more obvious for the upper limb than for
the lower limb. It is possible that this derives from the
higher complexity of the cortical control of the upper
limb, more influenced by distorted cortical oscillations
in comparison with the more simple and automatic
scheme of the lower limb motility.
A limitation of our study derives from the fact that we
evaluated the extent of the area showing MEG-EMG
coherent beta oscillations at sensor level. Magnetic field
spread can cause smearing of the effect of the neural
generators at the surface and induce spurious correla-
tions between MEG sensors. An analysis at source-space
level should thus enhance the spatial resolution of our
study. However, in our study we compared the coher-
ence patterns obtained from EPM1 patients versus
controls and evaluated their differences from a statistical
point of view. Therefore, we expect that if our CMC
results resulted inflated or smeared by magnetic field
spread, this was also true for the subject groups controls
in a comparable way, thus limiting this type of bias. To
better understanding the role of cortical regions outside
the contralateral sensorimotor cortex and their involve-
ment in generating myoclonus, further studies evaluating
both CMC and cortico-cortical effective connectivity
and network topology may add useful information.
Conclusions
Our observation shows that the strongly enhanced beta-
CMC found in EPM1 patients during cortical myoclonus
does not represent a merely quantitative phenomenon
due to increased neuronal synchronization but resides
on a disease-dependent change of the neuronal network.
Actually, in EPM1 patients enhanced beta-CMC occured
in an enlarged cortical area, but in a restricted range of
low-beta frequencies while in controls beta-CMC in-
volved broader and less stable frequencies. The signifi-
cant relationship between beta-CMC peak frequency
and the severity of the motor impairment discloses the
degree of pathological network reorganization and may
represent a useful neurophysiological marker for the
patients’ evaluation and follow-up.
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